Nurix Therapeutics, Inc.

This is a first-in-human study testing a new oral drug called NX-1607 in adults with advanced cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the body handles the drug, both alone and combined with a common chemot…

This study is testing an experimental oral drug called NX-5948 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to standard treatments. The drug works differently than previous medications by completely…

This is a first-in-human study testing a new oral drug called NX-5948 in adults with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll …

This early-stage study aims to understand how a new drug, NX-5948, is absorbed by the body when taken as a tablet versus a capsule. Researchers will also check if eating food or taking a common heartburn medicine changes how the drug works. The study involves 18 healthy adult vol…